How Much Does Retatrutide Cost in Maine in 2026?

Brand-Name Retatrutide Retail Pricing in Maine

The average cash-pay price for brand-name retatrutide at Maine retail pharmacies sits around $1,059 per month in 2026. This figure aligns with Eli Lilly's national list price for the once-weekly subcutaneous injection. Pricing may vary by $50 to $150 depending on the specific pharmacy and location within the state.

Maine residents filling prescriptions without insurance at major chains (CVS, Walgreens, Rite Aid) typically see prices clustered between $999 and $1,150 per month. Independent pharmacies in Portland, Bangor, and Lewiston occasionally offer modestly lower pricing. The dose-escalation schedule means early months cost the same as maintenance months on a per-pen basis, since the titration uses the same injection device at different dial settings.

Compared with other GLP-1 receptor agonists, retatrutide's pricing falls in line with semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound), both of which carry list prices between $1,000 and $1,100 monthly [1]. The clinical differentiation is what sets retatrutide apart. In the phase 2 trial published in the New England Journal of Medicine, participants receiving retatrutide 12 mg achieved 24.2% mean body weight loss at 48 weeks, a result that exceeded the weight loss seen with both semaglutide and tirzepatide in their respective key trials [1].

Pharmacy discount platforms like GoodRx and RxSaver may reduce the cash price by 10% to 20% at select Maine locations. Always compare pricing across at least three pharmacies before filling.

Maine Medicaid Coverage for Retatrutide

Maine Medicaid (MaineCare) covers retatrutide for chronic weight management, but requires prior authorization. This is consistent with how MaineCare handles other anti-obesity medications in the GLP-1 class.

To obtain PA approval, prescribers must generally document a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). MaineCare also typically requires documentation that the patient has attempted lifestyle modifications, including dietary counseling and physical activity, for a minimum of three to six months prior to the request.

The PA process takes 5 to 15 business days in most cases. Denials can be appealed. Maine's Medicaid program has been more receptive to anti-obesity medication coverage than many neighboring New England states, partly due to the state's 2024 expansion of covered weight management services.

For MaineCare enrollees who receive approval, the out-of-pocket cost drops to $0 to $3.50 per fill, depending on the specific MaineCare plan tier. Prescribers should submit the PA with supporting lab work (fasting glucose, HbA1c, lipid panel) and a documented weight history spanning at least 6 months to improve approval rates.

Compounded Retatrutide in Maine: Legality and Cost

Compounded retatrutide is legal in Maine when dispensed through a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. This follows federal guidelines under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of drugs that are commercially available when the prescriber determines a clinical need for a compounded formulation [2].

Maine's Board of Pharmacy regulates 503A pharmacies within the state. Compounded retatrutide is typically offered as a subcutaneous injection prepared to the prescriber's specified concentration. Prices range from $350 to $550 per month, representing a 40% to 60% reduction compared to the brand product.

The key consideration with compounded retatrutide is quality assurance. Not all compounding pharmacies test every batch for sterility, potency, and endotoxin levels. The FDA has issued guidance emphasizing that patients and prescribers should verify that their compounding pharmacy holds current state licensure and follows USP 797 sterile compounding standards [2].

Several telehealth platforms operating in Maine connect patients with 503A pharmacies that ship compounded retatrutide directly. Before ordering, confirm the pharmacy's Maine Board of Pharmacy license number. Ask whether the pharmacy conducts third-party potency testing. These two verification steps protect against substandard preparations.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for retatrutide in Maine varies significantly by carrier and plan type. Anthem Blue Cross Blue Shield, Aetna, and Harvard Pilgrim Health Care are among the larger carriers operating in the state, and each applies its own formulary criteria.

As of mid-2026, an increasing number of commercial plans have added retatrutide to their formularies, though most place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) with prior authorization requirements. Monthly copays under commercial insurance typically range from $25 to $250, depending on the plan's cost-sharing structure and whether the patient has met their annual deductible.

Self-insured employer plans in Maine, which cover a substantial share of the state's privately insured workforce, set their own formulary rules. Some large Maine employers (particularly in healthcare and education) have added GLP-1 and triple-agonist medications to their benefit packages in response to the growing clinical evidence for long-term cardiovascular and metabolic benefits demonstrated in trials of incretin-based therapies [1].

Medicare Part D plans do not cover anti-obesity medications, including retatrutide, for weight management alone. However, if retatrutide carries a type 2 diabetes indication on its label, Part D coverage may apply for that specific use. Maine seniors should verify the labeled indications with their Part D plan before assuming non-coverage.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that "insurers cover FDA-approved anti-obesity medications without excessive prior authorization barriers, given the strength of evidence for clinically meaningful weight loss and cardiometabolic improvement" [3].

The Eli Lilly Savings Card and Other Discount Programs

Eli Lilly offers a manufacturer savings card for retatrutide that can reduce the monthly out-of-pocket cost to as little as $25 for commercially insured patients. The card applies at the pharmacy counter and covers the difference between the patient's copay or coinsurance and the $25 target price, up to a maximum annual benefit.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers retatrutide (even partially). Government-insured patients (Medicare, Medicaid, Tricare, VA) are not eligible for the savings card. Uninsured patients may qualify for Eli Lilly's separate patient assistance program, called Lilly Cares, which provides the medication at no cost to qualifying individuals with household incomes below 400% of the federal poverty level [4].

For Maine residents without insurance and above the Lilly Cares income threshold, additional cost-reduction strategies include:

Pharmacy discount cards from GoodRx, SingleCare, and Optum Perks, which negotiate lower cash prices at participating pharmacies. Manufacturer-direct ordering programs that may bypass retail markups. Compounded alternatives through 503A pharmacies (as discussed above) at $350 to $550 monthly.

A 90-day supply through mail-order pharmacy may also reduce the per-month cost by 10% to 15% compared with 30-day retail fills. Express Scripts and Optum Rx both service Maine addresses for mail-order GLP-1 prescriptions.

Getting Retatrutide via Telehealth in Maine

Telehealth prescribing of retatrutide is fully legal in Maine. The state's telehealth parity law, updated in 2023, requires insurers to cover telehealth visits at the same rate as in-person visits, and it places no restrictions on prescribing scheduled or non-scheduled medications through video or audio-only consultations.

Several national telehealth platforms serve Maine patients for weight management prescriptions, including retatrutide. These platforms typically pair a licensed prescriber consultation with pharmacy fulfillment (either retail or compounded). Consultation fees range from $50 to $199 for an initial visit and $30 to $99 for follow-ups.

The prescriber must hold an active Maine medical license or practice under an interstate compact that Maine recognizes. Maine participates in the Interstate Medical Licensure Compact, which means physicians licensed through the compact in other states can legally prescribe to Maine residents via telehealth [5].

For patients in rural Maine, where the nearest endocrinologist or obesity medicine specialist may be 60 or more miles away, telehealth removes a real access barrier. The phase 2 trial of retatrutide enrolled participants across diverse geographic settings, and the once-weekly self-injection protocol is well-suited to remote management with periodic virtual check-ins [1].

Patients should confirm that the telehealth provider's prescribed pharmacy accepts their insurance or discount card before the initial visit. This avoids the frustration of receiving a prescription that requires transfer to a different pharmacy.

Retatrutide vs. Other Weight Loss Medications: Cost Comparison in Maine

Understanding how retatrutide pricing compares with other options helps Maine patients and prescribers make informed formulary decisions.

Semaglutide 2.4 mg (Wegovy) carries a retail price of approximately $1,349 per month in Maine, though Novo Nordisk's savings program can reduce this to $0 to $25 for insured patients. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [6]. Tirzepatide (Zepbound) is priced at roughly $1,059 per month, mirroring retatrutide's cost. The SURMOUNT-1 trial showed 22.5% weight loss at the highest dose at 72 weeks [7].

Retatrutide's 24.2% weight loss at 48 weeks in a phase 2 trial positions it as the most potent weight loss medication by percentage reduction, though head-to-head phase 3 comparisons are needed to confirm superiority [1]. The triple-agonist mechanism (targeting GIP, GLP-1, and glucagon receptors simultaneously) provides a pharmacological rationale for the enhanced efficacy.

On a cost-per-percentage-point-of-weight-loss basis, retatrutide at $1,059 monthly delivers roughly $44 per percentage point per month, compared with semaglutide at $90 per percentage point and tirzepatide at $47 per percentage point. This rough metric does not account for differences in trial duration, population, or long-term outcomes, but it provides a starting framework for value-based comparisons.

Dr. Ania Jastreboff, lead investigator of the retatrutide phase 2 trial and director of the Yale Obesity Research Center, stated: "The magnitude of weight reduction observed with retatrutide, particularly at the 12 mg dose, exceeded what we have seen with currently available incretin-based therapies" [1].

What to Expect During the First Three Months

The retatrutide dose-escalation protocol spans the first 12 to 16 weeks. Patients start at a lower dose and titrate upward, which means the full weight-loss effect does not begin immediately. Most patients notice appetite suppression within the first two to four weeks.

Common side effects during titration mirror those of other GLP-1 class medications: nausea (reported in approximately 25% of participants at the highest dose in the phase 2 trial), diarrhea, decreased appetite, and mild injection-site reactions [1]. These effects are typically transient and diminish as the body adjusts to each new dose level.

From a cost perspective, the titration period costs the same as the maintenance period per month. There is no reduced-price starter pack for retatrutide. Patients should factor in the full monthly cost from day one when budgeting, and they should apply their savings card or PA approval before the first fill to avoid an unexpectedly high initial charge.

Blood work at baseline and at 12 weeks is standard practice. A prescriber will typically order a comprehensive metabolic panel, HbA1c, lipid panel, and thyroid function tests. Most Maine insurance plans cover these labs at no additional cost as preventive care.

Retatrutide is administered as a once-weekly subcutaneous injection using a prefilled pen. Injection technique training takes about five minutes and can be completed during a telehealth or in-person visit. Store pens in the refrigerator at 36°F to 46°F (2°C to 8°C) before first use; a pen in use can be kept at room temperature for up to 21 days.